PRO – Reena Khanna, MD, MSc., FRCP(C)

Associate Professor of Medicine
Department of Medicine, Division of Gastroenterology
University of Western Ontario
London, Ontario

Sunday, November 21, 2021

10:00 am - 10:30 am

Debate: Is Anti-TNF the first drug of choice in individuals with moderate to severe IBD? 

Given the ever increasing armamentarium of therapies for the management of IBD, clinicians are faced with the dilemma as to which is the drug of choice in individuals with moderate to severe UC and CD. In this session, the presenters will debate the topic "Is anti-TNF the first drug of choice in individuals with moderate to severe IBD?" and provide data on the safety and efficacy of the major biologic classes e.g. anti-TNFs, anti-integrins and anti-IL12/23.

Dr. Reena Khanna is an Associate Professor of Medicine at the University of Western Ontario, and a Clinician Researcher in the Program for Experimental Medicine. She completed her MD and Internal Medicine residency at the University of Western Ontario, Gastroenterology fellowship at McMaster University.   Dr. Khanna completed an advanced fellowship in inflammatory bowel disease (IBD) at the Cleveland Clinic, followed by a research fellowship in international IBD clinical trials at the University of Western Ontario.   She completed an MSc in clinical epidemiology at McMaster University.  Her clinical and research interest are clinical trial design, new therapeutics, outcome measures.  She has designed, conducted and published several studies, including the first cluster study in IBD.  Dr. Khanna holds international grants and was awarded the Crohn’s Colitis Canada’s rising star award for her research contributions.